Assuntos
Doenças da Córnea/diagnóstico , Doenças do Prematuro/diagnóstico , Ceratite/diagnóstico , Doenças da Córnea/complicações , Doenças da Córnea/congênito , Esotropia/complicações , Esotropia/congênito , Esotropia/diagnóstico , Feminino , Humanos , Recém-Nascido , Doenças do Prematuro/patologia , Ceratite/complicações , Ceratite/congênito , Retinose Pigmentar/complicações , Retinose Pigmentar/congênito , Retinose Pigmentar/diagnóstico , Transtornos da Visão/congênito , Transtornos da Visão/diagnóstico , Transtornos da Visão/etiologiaAssuntos
Anormalidades do Olho/complicações , Glaucoma/congênito , Glaucoma/diagnóstico , Glaucoma/etiologia , Disco Óptico/anormalidades , Coloboma/complicações , Coloboma/diagnóstico , Diagnóstico Diferencial , Anormalidades do Olho/diagnóstico , Humanos , Lactente , Masculino , Disco Óptico/diagnóstico por imagem , Nervo Óptico/anormalidadesRESUMO
Posterior capsule opacification (PCO) is the most common complication after cataract surgery, with an incidence of 30%. It tends to be considered a normal event in the natural history of cataract surgery. Better understanding of its pathophysiology and advancement of intraocular lens material and design along with the improvement of phacoemulsification technique have contributed to decrease the incidence of PCO. Although treatment by Nd: YAG laser posterior capsulotomy is quick and non-invasive, the opening of the posterior capsule may be associated with numerous complications. Prevention remains the best measure for controlling this pathology.
Assuntos
Opacificação da Cápsula , Adulto , Opacificação da Cápsula/diagnóstico , Opacificação da Cápsula/patologia , Opacificação da Cápsula/prevenção & controle , Opacificação da Cápsula/terapia , Extração de Catarata/efeitos adversos , Criança , Diagnóstico Diferencial , Humanos , Terapia a LaserRESUMO
OBJECTIVE: Assessment of cancer screening in the context of venous thromboembolic disease (VTE) remains controversial. We tried to characterize a population at high risk of developing cancer among patients suffering from VTE. METHOD: We conducted a retrospective ancillary case-control study among patients with VTE who later had a positive diagnosis of cancer. We assessed the association of cancer with characteristic features of VTE and with the results for four biological markers. RESULTS: Our population included 142 patients (53% men, median age 71 years). Two years after VTE, 24 patients (17%) had cancer. Median values for D-dimers, fibrin monomers and SP-selectin were significantly higher among patients who developed cancer. Logistic regression enabled us to identify two parameters targeting patients with a high risk of cancer: bilateral venous thrombosis (OR: 4.41, 95%CI: 1.41-13.78, P=0.01) and D-dimers superior to 3.8 µg/mL (OR: 3.68, 95%CI: 1.36-9.94, P=0.01). The information provided by these two characteristics was additive; 58% of patients in our population who had both factors developed cancer. CONCLUSION: Bilateral venous thrombosis and D-dimers superior to 3.8 µg/mL are highly associated with carcinoma. This result requires a prospective validation. It could be useful in limiting the screening process to the population most at risk.
